RAPP as reported
- Net Income
- −$137M
Net Income · +55% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$97M
Free Cash Flow · +26% year on year · trailing twelve months to Q2 2026
- EPS
- −$3.03
EPS · +48% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$137M | +55% | Q2 2026 |
| EPS | −$3.03 | +48% | Q2 2026 |
| ROE | −24% | n/a | Q2 2026 |
| ROA | −23% | n/a | Q2 2026 |
| Free Cash Flow | −$97M | +26% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Rapport Therapeutics, Inc. (RAPP) - Revenue & ProfitRevenue & ProfitRapport Therapeutics, Inc. (RAPP)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com